Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
BMJ Open|September 17, 2021
Quick-Wee versus bladder stimulation to collect midstream urine from precontinent infants under 1 year of age: a study protocol for a randomised controlled trial (ES.Stimquick.U)Sarah Marchal, Jade Janicot, Julie Salicis, et al.
The Journal of Infectious Diseases|September 11, 2019
Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) StudyLene Ryom, Jens Dilling Lundgren, Peter Reiss, et al.
The Journal of Infectious Diseases|July 9, 2020
The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D StudyLene Ryom, Jens D Lundgren, Peter Reiss, et al.
Neuromodulation : Journal of the International Neuromodulation Society|April 22, 2021
Occipital Nerve Stimulation for Refractory Chronic Cluster Headache: A Cost-Effectiveness StudyJulie Bulsei, Aurélie Leplus, Anne Donnet, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 8, 2024
Integrase Strand Transfer Inhibitor-Related Changes in Body Mass Index and Risk of Diabetes: A Prospective Study From the RESPOND Cohort ConsortiumDhanushi Rupasinghe, Loveleen Bansi-Matharu, Matthew Law, et al.
The Lancet. HIV|April 15, 2024
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohortsDathan M Byonanebye, Mark N Polizzotto, Fernando Maltez, et al.
HIV Medicine|March 2, 2022
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortiumDathan M Byonanebye, Mark N Polizzotto, Bastian Neesgaard, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 13, 2024
Switching From Dupilumab to Tralokinumab or Janus Kinase Inhibitors in Cases of Ocular and/or Facial Adverse Events in Patients With Atopic Dermatitis: A Multicenter Retrospective StudyAlexandre Beyrouti, Juliette Deuze, Eric Fontas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 13, 2023
Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort StudyHortensia Álvarez, Amanda Mocroft, Lene Ryom, et al.
The Lancet. HIV|September 23, 2021
Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortiumLoveleen Bansi-Matharu, Andrew Phillips, Cristiana Oprea, et al.
Pageof 9